Wockhardt Ltd

The stock has now surged 21.47% over two days, powered by the US FDA's acceptance of its New Drug Application (NDA) for the breakthrough antibiotic Zaynich. The approval marks a landmark moment as it is the first time an Indian pharmaceutical company has had an NDA for a completely new chemical entity accepted by the US regulator. Zaynich, built on a novel β-lactam enhancer mechanism, has also received Fast Track status for its potential to address urgent medical needs. With over a decade of research behind it, the drug has demonstrated strong efficacy against highly resistant Gram-negative pathogens and has already helped critically ill patients in India and the US through compassionate use. The acceptance reflects confidence in Wockhardt's scientific depth and its global-standard development program. Wockhardt is a global pharmaceutical and biotechnology company focused on developing innovative anti-infective solutions. The company posted a consolidated net profit of Rs 78 crore in Q2 FY26 compared with a net loss of Rs 22 crore a year earlier, while net sales declined 3.34% YoY to Rs 782 crore. Powered by Capital Market - Live

Wockhardt today announced that the United States Food and Drug Administration (US FDA) has formally accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich. The NDA was originally filed on September 30, 2025, and its acceptance marks a transformative moment'not only for Wockhardt, but also for the entire Indian pharmaceutical industry. This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA. Zaynich has been granted Fast Track designation by the US FDA, recognizing its potential to address urgent and unmet medical needs. As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review. A novel '-lactam enhancer mechanism based Zaynich has garnered international attention for its potent activity against highly resistant Gram-negative pathogens'microbes responsible for prolonged hospitalizations and significant mortality worldwide. Its life-saving impact has already been demonstrated through compassionate use in critically ill patients in both India and the United States. Over the past decade, Zaynich has become one of the most extensively studied antibiotics globally, reflecting a comprehensive, science-driven development program initiated by Wockhardt in 2011. The company has successfully navigated a demanding non-clinical, clinical and regulatory pathway.Powered by Capital Market - Live

Aegis Vopak Terminals Ltd, JM Financial Ltd, Star Health & Allied Insurance Company Ltd, KFin Technologies Ltd are among the other stocks to see a surge in volumes on NSE today, 01 December 2025.Wockhardt Ltd notched up volume of 98.36 lakh shares by 14:14 IST on NSE, a 34.53 fold spurt over two-week average daily volume of 2.85 lakh shares. The stock rose 18.76% to Rs.1,466.70. Volumes stood at 4.46 lakh shares in the last session.Aegis Vopak Terminals Ltd notched up volume of 50.21 lakh shares by 14:14 IST on NSE, a 16.58 fold spurt over two-week average daily volume of 3.03 lakh shares. The stock rose 5.53% to Rs.274.95. Volumes stood at 3.81 lakh shares in the last session.JM Financial Ltd saw volume of 541.65 lakh shares by 14:14 IST on NSE, a 15.25 fold spurt over two-week average daily volume of 35.52 lakh shares. The stock increased 7.12% to Rs.155.70. Volumes stood at 25.34 lakh shares in the last session.Star Health & Allied Insurance Company Ltd recorded volume of 19.02 lakh shares by 14:14 IST on NSE, a 6.54 times surge over two-week average daily volume of 2.91 lakh shares. The stock lost 1.01% to Rs.483.00. Volumes stood at 3.45 lakh shares in the last session.KFin Technologies Ltd clocked volume of 25.95 lakh shares by 14:14 IST on NSE, a 4.32 times surge over two-week average daily volume of 6.01 lakh shares. The stock gained 3.66% to Rs.1,095.00. Volumes stood at 4.93 lakh shares in the last session.Powered by Capital Market - Live

The aforementioned NDA was filed on 30 September 2025. This is the first time in history that an NDA for a new chemical entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA,' the company said in a statement. Zaynich has been granted 'fast track' designation by the US FDA, recognizing its potential to address urgent and unmet medical needs. As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review. Zaynich, a β-lactam enhancer, has drawn international interest for its activity against resistant gram-negative bacteria, which are linked to long hospital stays and high mortality. It has been used in critically ill patients in India and the United States. Wockhardt is a global pharmaceutical and biotechnology company focused on developing anti-infective solutions. The company had reported a consolidated net profit of Rs 78 crore in Q2 FY26 as against a net loss of Rs 22 crore recorded in Q2 FY25. Net sales declined 3.34% to Rs 782 crore in Q2 FY26 as compared with Q2 FY25. Powered by Capital Market - Live

JM Financial Ltd, TVS Holdings Ltd, Tamilnad Mercantile Bank Ltd and Sharda Motor Industries Ltd are among the other gainers in the BSE's 'A' group today, 01 December 2025.Wockhardt Ltd spiked 9.27% to Rs 1347.85 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 40468 shares were traded on the counter so far as against the average daily volumes of 31541 shares in the past one month. JM Financial Ltd surged 8.02% to Rs 157. The stock was the second biggest gainer in 'A' group. On the BSE, 23.23 lakh shares were traded on the counter so far as against the average daily volumes of 2.13 lakh shares in the past one month. TVS Holdings Ltd soared 6.07% to Rs 15247.1. The stock was the third biggest gainer in 'A' group. On the BSE, 588 shares were traded on the counter so far as against the average daily volumes of 327 shares in the past one month. Tamilnad Mercantile Bank Ltd advanced 5.72% to Rs 536.25. The stock was the fourth biggest gainer in 'A' group. On the BSE, 1.42 lakh shares were traded on the counter so far as against the average daily volumes of 11655 shares in the past one month. Sharda Motor Industries Ltd exploded 5.63% to Rs 982.95. The stock was the fifth biggest gainer in 'A' group. On the BSE, 7193 shares were traded on the counter so far as against the average daily volumes of 11396 shares in the past one month. Powered by Capital Market - Live

Wockhardt Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1278.8, down 2.48% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.08% on the day, quoting at 26088.15. The Sensex is at 85340.46, up 0.13%.Wockhardt Ltd has eased around 1.21% in last one month.Meanwhile, Nifty Pharma index of which Wockhardt Ltd is a constituent, has increased around 0.99% in last one month and is currently quoting at 22580.95, down 0.22% on the day. The volume in the stock stood at 1.23 lakh shares today, compared to the daily average of 6.44 lakh shares in last one month.The PE of the stock is 151.15 based on TTM earnings ending September 25.Powered by Capital Market - Live

Net profit of Wockhardt reported to Rs 78.00 crore in the quarter ended September 2025 as against net loss of Rs 22.00 crore during the previous quarter ended September 2024. Sales declined 3.34% to Rs 782.00 crore in the quarter ended September 2025 as against Rs 809.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales782.00809.00 -3 OPM %22.7613.60 - PBDT144.0046.00 213 PBT91.00-9.00 LP NP78.00-22.00 LP Powered by Capital Market - Live

Wockhardt will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live

Wockhardt today announced the submission of New Drug Application (NDA) to the U.S. Food and Drug Administration (US FDA) for its novel antibacterial agent Zidebactam-Cefepime injection (WCK 5222, ZAYNICH'). The NDA seeks approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with or without concurrent bacteremia caused by Gram-negative bacteria including multidrug-resistant (MDR). In US and EU, more than 8 Million cUTI cases are reported every year, reflecting the global burden of Gram negative infections. This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company, a momentous achievement for Indian innovation. Amidst the escalating global crisis of antimicrobial resistance (AMR), Zidebactam-Cefepime represents a first-in-class '-lactam enhancer and '-lactam combination, introducing a novel mechanism of action to combat some of the most difficult-to-treat infections particularly those that remain unresponsive to approved antibiotics, including those that are recently approved. Clinical and non-clinical studies have demonstrated its potent activity against multi-drug resistant (MDR) and extreme drug resistant (XDR) Gram-negative pathogens, including those harbouring NDM carbapenemases and PBP mutations. A Phase II study undertaken has demonstrated its efficacy against diverse carbapenem-resistant infections. The NDA submission follows the successful completion of a pivotal Phase III global clinical trial (ENHANCE 1), conducted across 64 sites in India, USA, Bulgaria, Estonia, Lithuania, Poland, Slovakia, Mexico, and China. The program is supported by a robust clinical development package, including nine Phase I studies conducted in the U.S. and China, a Phase II study conducted in India and a multinational Phase III trial evaluating efficacy in cUTI, including pyelonephritis. Zidebactam-cefepime has been granted qualified infectious disease product (QIDP) and Fast Track Designation by US FDA. Gram-negative infections have become increasingly difficult to treat due to wide spread resistance to multiple classes of antibiotics. Zaynich' has the potential to treat a broad range of infections caused by MDR or XDR pathogens including Enterobacterales and Pseudomonas aeruginosa and A. baumannii. Powered by Capital Market - Live

Mangalore Refinery And Petrochemicals Ltd, Sammaan Capital Ltd, Bharat Forge Ltd, Petronet LNG Ltd are among the other stocks to see a surge in volumes on NSE today, 29 September 2025.Wockhardt Ltd notched up volume of 67.62 lakh shares by 14:14 IST on NSE, a 14.76 fold spurt over two-week average daily volume of 4.58 lakh shares. The stock rose 15.09% to Rs.1,538.20. Volumes stood at 23.24 lakh shares in the last session.Mangalore Refinery And Petrochemicals Ltd saw volume of 126.1 lakh shares by 14:14 IST on NSE, a 8.43 fold spurt over two-week average daily volume of 14.96 lakh shares. The stock increased 5.46% to Rs.134.35. Volumes stood at 18.44 lakh shares in the last session.Sammaan Capital Ltd saw volume of 1170.26 lakh shares by 14:14 IST on NSE, a 6.25 fold spurt over two-week average daily volume of 187.29 lakh shares. The stock increased 11.67% to Rs.153.91. Volumes stood at 204.12 lakh shares in the last session.Bharat Forge Ltd notched up volume of 47.71 lakh shares by 14:14 IST on NSE, a 4.98 fold spurt over two-week average daily volume of 9.58 lakh shares. The stock rose 3.64% to Rs.1,224.10. Volumes stood at 7.05 lakh shares in the last session.Petronet LNG Ltd notched up volume of 80.94 lakh shares by 14:14 IST on NSE, a 4.65 fold spurt over two-week average daily volume of 17.40 lakh shares. The stock rose 4.68% to Rs.279.40. Volumes stood at 18.95 lakh shares in the last session.Powered by Capital Market - Live